Evidence map›Paper›PMID 25576067›Full record

ArticleClinical trials (London, England)2015

A novel use of a statewide telecolposcopy network for recruitment of participants in a Phase I clinical trial of a human papillomavirus therapeutic vaccine.

Shawna L Stratton, Horace J Spencer, William W Greenfield, Gordon Low, Wilbur C Hitt, Charles M Quick, Susanne K Jeffus, Victoria Blackmon, Mayumi Nakagawa

Abstract readClinical Trial, Phase I
In one paragraph

Article in Clinical trials (London, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Telehealth in emergency medicine: A consensus conference to map the intersection of telehealth and emergency medicine.Academic emergency medicine : official journal of the Society for Academic Emergency Medicine · 2021
    Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Shawna L StrattonClinical Research Services Core, Translational Research Institute, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR, USA.
Horace J SpencerDepartment of Biostatistics, College of Medicine, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR, USA.
William W GreenfieldDepartment of Obstetrics and Gynecology, College of Medicine, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR, USA.
Gordon LowDepartment of Obstetrics and Gynecology, College of Medicine, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR, USA.
Wilbur C HittDepartment of Obstetrics and Gynecology, College of Medicine, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR, USA.
Charles M QuickDepartment of Pathology, College of Medicine, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR, USA.
Susanne K JeffusDepartment of Pathology, College of Medicine, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR, USA.
Victoria BlackmonDepartment of Obstetrics and Gynecology, College of Medicine, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR, USA.
Mayumi NakagawaDepartment of Pathology, College of Medicine, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR, USA mnakagawa@uams.edu.
University of Arkansas for Medical Sciences · US

Funding

Understanding and Enhancing T-Cell Responses to High Risk Human Papillomaviruses-RenewalR01CA143130 · NCI · UNIV OF ARKANSAS FOR MED SCIS · PI NAKAGAWA, MAYUMI · 2010 to 2025
$10.0M
Arkansas Center for Clinical and Translational ResearchUL1TR000039 · NCATS · UNIV OF ARKANSAS FOR MED SCIS · PI BECK, CORNELIA MARIE, JAMES, LAURA P · 2012 to 2014
$10.0M
NCATS NIH HHS UL1 TR000039NCATS NIH HHS UL1TR000039NCI NIH HHS R01 CA143130PHS HHS 1 H2AIT16616PHS HHS 6 H2ARH24765-02-01
6 · The paper itself

Abstract

backgroundHistorically, recruitment and retention of young women in intervention-based clinical trials have been challenging. In August 2012, enrollment for a clinical trial testing of an investigational human papillomavirus therapeutic vaccine called PepCan was opened at our institution. This study was an open-label, single-arm, single-institution, dose-escalation Phase I clinical trial. Women with recent Papanicolaou smear results showing high-grade squamous intraepithelial lesions or results that could not rule out high-grade squamous intraepithelial lesion were eligible to enroll. Patients with biopsy-confirmed high-grade squamous intraepithelial lesion were also eligible. Colposcopy was performed at the screening visit, and participants became eligible for vaccination when the diagnosis of high-grade squamous intraepithelial lesion was confirmed with biopsy and other inclusion criteria were met. The aim of this study was to identify strategies and factors effective in recruitment and retention of study participants.

methodsPotential vaccine candidates were recruited through direct advertisement as well as referrals, including referrals through the Arkansas telecolposcopy network. The network is a federally funded program, administered by physicians and advanced practice nurses. The network telemedically links rural health sites and allows physician-guided colposcopy and biopsies to be conducted by advanced practice nurses. A variety of strategies were employed to assure good retention, including face-to-face contact with the study coordinator at the time of consent and most of study visits; frequent contact using text messaging, phone calls, and e-mails; and creation of a private Facebook page to improve communication among research staff and study participants. A questionnaire, inquiring about motivation for joining the study, occupation, education, household income, number of children, and number of sexual partners, was administered at the screening visit with the intent of identifying factor(s) associated with recruitment and retention.

resultsA total of 37 participants were enrolled between September 2012 and March 2014. The largest proportion of participants (46%) was enrolled from the telecolposcopy network. Others were enrolled through outside institutions (43%), in-house referrals (8%), or direct advertisement (3%). Most participants were motivated to join the study to take care of their health issues. Only two participants joined the Facebook private page. Of the 24 participants who qualified for vaccination, only 1 terminated early due to an unanticipated move.

conclusionThe availability of a large number of potential participants from the telecolposcopy network increased recruitment to this clinical trial by 85% over other traditional means of recruitment. The telecolposcopy network is not only a means of providing a gynecological service to women who otherwise would forego care but also a novel and valuable resource in recruiting participants for a clinical trial.

Indexed as

Patient SelectionAdultColposcopyCommunicationFemaleHumansMiddle AgedPapanicolaou TestPapillomavirus VaccinesResearch DesignRural Health ServicesSocioeconomic FactorsSquamous Intraepithelial Lesions of the CervixTelemedicinePapillomavirus VaccinesFacebookhuman papillomavirusrecruitmentTelecolposcopy networktherapeutic vaccine

Identifiers

PMID25576067
PMCPMC4424105
OpenAlexW2096156494

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.